Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
31 studies found for:    "Diffuse systemic sclerosis"
Show Display Options
RSS Create an RSS feed from your search for:
"Diffuse systemic sclerosis"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: Abatacept;   Drug: Placebo
2 Completed Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
Condition: Early Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: Methotrexate;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide
3 Recruiting Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
Conditions: Scleroderma, Diffuse;   Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: IVA337;   Drug: Placebo
4 Unknown  Serial Night Time Position Splint on Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Interventions: Device: Serial night time position splint;   Drug: Drug treatment
5 Completed Fresolimumab In Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Intervention: Drug: Fresolimumab
6 Active, not recruiting Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: JBT-101;   Drug: Placebo;   Drug: Part B Open-Label Extension
7 Recruiting Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: atorvastatin;   Drug: Placebo
8 Active, not recruiting Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Ambrisentan
9 Unknown  High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
Condition: Scleroderma, Diffuse
Intervention: Drug: N-acetylcysteine (NAC)
10 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
11 Active, not recruiting Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Belimumab
12 Completed Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Condition: Systemic Sclerosis
Intervention: Drug: Relaxin
13 Recruiting Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: SAR156597 (ACT14604);   Drug: Placebo
14 Completed Mycophenolate Mofetil in Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Intervention: Drug: Mycophenolate Mofetil
15 Unknown  AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: Hyperimmune caprine serum;   Drug: Albumin
16 Recruiting IVIG Treatment in Systemic Sclerosis
Conditions: Systemic Sclerosis;   Diffuse Scleroderma
Intervention: Biological: Privigen
17 Terminated Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: Imatinib mesylate;   Other: Placebo
18 Recruiting Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
Conditions: Scleroderma;   Cardiac Involvement;   Autologous Stem Cell Transplantation
Intervention: Drug: Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
19 Recruiting Autologous SCT for Progressive Systemic Sclerosis: a Prospective NIS Study
Condition: Autoimmune Diseases
Intervention: Procedure: Autologous HSCT
20 Withdrawn A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Condition: Scleroderma
Interventions: Drug: BMS-986020;   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.